XML 147 R62.htm IDEA: XBRL DOCUMENT v3.25.3
Commitments and Contingencies (Details Narrative) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
May 15, 2025
Grant repyable $ 511,617      
Future research and collaboration commitments 1,368,809      
Long-term debt payable 6,479,333      
Operating Lease Right of Use Obligations [Member]        
Operating lease liabilities 91,358      
Operating lease expense 166,864      
Short term lease costs 83,309      
Gustave Roussy [Member]        
Additional cost of company 119,540      
Due to related party 119,540      
Collaborative obligations amount due $ 17,928      
Convertible Notes Payable [Member]        
Stock upon repayment or conversion description ownership limitation equal to 4.99% of the Company’s outstanding shares of common stock; provided, that if Lind and its affiliates beneficially own in excess of 4.99% of the Company’s outstanding shares of common stock, then such limitation shall automatically increase to 9.99% so long as Lind and its affiliates own in excess of 4.99% of such common stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon Lind and its affiliates ceasing to own in excess of 4.99% of such common stock). Additionally, the issuance in the aggregate of any Note Shares and Warrant Shares in excess of 19.99% of the outstanding common stock shall be subject to stockholder approval in accordance with NYSE American Rule 713      
Initial fair value description (i) dividend yield of 0%; (ii) expected volatility of 99.99%; (iii) risk-free interest rate of 3.89%; (iv) discount rate of 42.95%; (v) simulated term of 1.92 years; (vi) estimated fair value of the shares of $0.45 per share; and (vii) various probability assumptions related to down round price adjustments. Subsequent changes in fair value are recognized in the statement of operations for each reporting period      
Convertible promissory note       $ 7,500,000
Warrant for purchase common stock $ 13,020,834      
Converted price       $ 0.72
Monthly payment 416,666      
Monthly payments 1,000,000      
Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]        
Additional cost of company 245,319      
Collaborative obligations amount due 245,319      
August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member]        
Additional cost of company 130,928      
Due to related party 130,928      
Collaborative obligations amount due 21,821      
July Thirty One Thousand Twenty Three [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]        
Additional cost of company 107,589      
Due to related party 81,447      
Collaborative obligations amount due 81,447      
October Two Thousand Twenty Four [Member] | National University of Taiwan Second [Member]        
Additional cost of company 402,250      
Due to related party 281,575      
Collaborative obligations amount due 120,675      
January 2024 [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]        
Additional cost of company 0      
Due to related party 0      
Collaborative obligations amount due 0      
January Two Thousand Twenty Four [Member] | University Medical Centre Amsterdam [Member]        
Additional cost of company 0      
Due to related party 0      
Collaborative obligations amount due 0      
VolitionRx [Member] | In 2016 [Member] | Long-term Debt [Member]        
Long-term debt payable $ 64,993      
Fixed interest rate on lease 7.82%      
Lease payable $ 294,603      
Managing Director's Agreement [Member]        
Due to related party 229      
Royalty payment $ 129,064      
Royality 6.00%      
Clinical Study Research Agreement [Member] | University of Taiwan [Member] | In 2018 [Member]        
Additional cost of company $ 510,000      
Collaborative obligations amount due $ 2,550,000      
Lease agreement expire period 3 years      
Restricted Stock Units [Member]        
Recognized total compensation expense $ 1,522,980   $ 527,940  
RSU vested in 2023 516,039      
RSU vested in 2024 479,001      
Unrecognized compensation expense 1,505      
Recognized total compensation expense 1,769,014 $ 937,567    
Restricted Stock Units [Member] | One        
Recognized total compensation expense 484,380      
RSU vested in 2023 224,055      
RSU vested in 2024 400,018      
Unrecognized compensation expense 979,980      
RSU vested in 2027 355,907      
Restricted Stock Units [Member] | Two        
RSU vested in 2023 0      
Unrecognized compensation expense 65,511      
RSU vested in 2027 65,511      
Recognized total compensation expense $ 606,864